Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New sedative may speed up endoscopy recovery

NCT ID NCT05836545

Symptom relief Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested remimazolam against midazolam for sedation during diagnostic upper gastrointestinal endoscopy. 132 healthy adults participated, and researchers measured total procedure time and sedation success. The goal is to see if remimazolam provides faster and more effective sedation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
remimazolam
What this could lead to
If remimazolam works better, it could offer faster and more reliable sedation for routine endoscopy procedures.
What could go wrong
This is a small, completed trial in healthy people, so results may not apply to all patients. Both drugs are already used, so no major breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

132 people

The number who actually took part.

Started

Apr 2023

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who agreed for this clinical trials * Patients who want diagnostic endoscopy under sedation * The total procedure time which is predicted within 15 minutes * ASA \>=2 * BMI more than 18.5kg/m2, less than 30kg/m2 Exclusion Criteria: * Patients who have stomach illness * Patients with respiratory disease * Mallampati Score\>=3 * Systolic BP \>160mmHg or \<90mmHg * Refractory Hypertension * Uncontrolled glaucoma * Severe liver failure or chronic kidney disease * Patients with drug abuse or alcohol abuse within 1 year * Patients who are sensitive for certain medication (such as benzodiazepine, remimazolam) * Obstructive sleep dyspnea patients * Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption * Pregnant, breast feeding patient

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy

Contacts and locations

Locations

  • Samsung Medical Center

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.